Is Akari Therapeutics PLC (AKTX) overvalued? · $17.2M cap
Akari Therapeutics PLC (AKTX) is a biotechnology company listed on US.
This page asks whether Akari Therapeutics PLC (AKTX) looks expensive on cached numbers — not a short thesis.
No cached income statement for AKTX, so there is no earnings base to call rich or cheap.
AKTX currently screens at market cap $17.2M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next AKTX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the AKTX stock page for the full model, not this heading.
Not investment advice.